I-Mab Signs Agreement to Divest its Assets and Business Oper

ROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ --  I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly

Related Keywords

California , United States , San Diego , Hong Kong , China , Rockville , Maryland , Hangzhou , Zhejiang , Ruyi , Xizang , Shanghai , Thailand , Chinese , Gigi Feng , Joseph Skelton , Tyler Ehler , Andrew Zhu , Richard Yeh , Shuai Chen , Jingwu Zang , Raj Kannan , Pamela Klein , Biopharma Hangzhou Co Ltd , Exchange Commission , Chairperson Of The Company , Biopharma Hong Kong Limitedi Mab , Biopharma Co Ltd , Cantor Fitzgerald , Nasdaq , Amneal Pharmaceuticals Inc , Hangzhou Company , Linkedin , I Mab Biopharma , Chief Executive Officer , Greater China , I Mab Biopharma Hong Kong Limited , Mab Hong , I Mab Hong Kong , Special Committee , Conor Chia Hung Yang , I Mab Shanghai , Interim Chairperson , Chief Financial Officer , Senior Vice President , Truist Securities , Amneal Pharmaceuticals , Securities Litigation Reform Act , New Drug , Biologics License Application , I Mab Signs Agreement , Business Operations , Thailand Business ,